Anacor Pharmaceuticals announces commencement of AN5568 trials

Anacor Pharmaceuticals announced that its collaboration partner, the Drugs for Neglected Diseases initiative, has commenced Phase 1 clinical studies of SCYX-7158, also referred to as AN5568, the first new oral drug candidate discovered specifically to combat human African trypanosomiasis, also known as sleeping sickness. AN5568 was discovered utilizing Anacor’s boron-based chemistry and is Anacor’s sixth compound to enter human clinical development since the company was started ten years ago.

View Comments (0)